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Abstract
Background: Hypertension (HT) and hand-foot skin reactions (HFSR) may be related to the activity of bevacizumab 
and sorafenib. We hypothesized that these toxicities would correspond to favorable outcome in these drugs, that HT 
and HFSR would coincide, and that VEGFR2 genotypic variation would be related to toxicity and clinical outcomes.
Methods: Toxicities (≥ grade 2 HT or HFSR), progression-free survival (PFS), and overall survival (OS) following 
treatment initiation were evaluated. Toxicity incidence and VEGFR2 H472Q and V297I status were compared to clinical 
outcomes.
Results: Individuals experiencing HT had longer PFS following bevacizumab therapy than those without this toxicity in 
trials utilizing bevacizumab in patients with prostate cancer (31.5 vs 14.9 months, n = 60, P = 0.0009), and bevacizumab 
and sorafenib in patients with solid tumors (11.9 vs. 3.7 months, n = 27, P = 0.052). HT was also linked to a > 5-fold OS 
benefit after sorafenib and bevacizumab cotherapy (5.7 versus 29.0 months, P = 0.0068). HFSR was a marker for 
prolonged PFS during sorafenib therapy (6.1 versus 3.7 months respectively, n = 113, P = 0.0003). HT was a risk factor for 
HFSR in patients treated with bevacizumab and/or sorafenib (OR(95%CI) = 3.2(1.5-6.8), P = 0.0024). Carriers of variant 
alleles at VEGFR2 H472Q experienced greater risk of developing HT (OR(95%CI) = 2.3(1.2 - 4.6), n = 170, P = 0.0154) and 
HFSR (OR(95%CI) = 2.7(1.3 - 5.6), n = 170, P = 0.0136).
Conclusions: This study suggests that HT and HFSR may be markers for favorable clinical outcome, HT development 
may be a marker for HFSR, and VEGFR2 alleles may be related to the development of toxicities during therapy with 
bevacizumab and/or sorafenib.
Background
The process of angiogenesis is crucial for carcinogenesis,
invasiveness and metastasis in several tumor types
including prostate, ovary, kidney, non-small cell lung and
colorectal cancer [1-3]. This process is governed by an
array of growth factors; however, vascular endothelial
growth factor (VEGF) and its major receptor in the
endothelium, VEGFR2, are predominant regulators of
this process [2]. Rising interest in angiogenic modulators
has led to the design and synthesis of several new mole-
c u l e s  t h a t  t a r g e t  t h e  V E G F  s i g n a l i n g  p a t h w a y ,  s u c h  a s
sorafenib, bevacizumab and sunitinib, which are cur-
rently approved for various solid tumors. There is wide
inter-individual variation in toxicity and clinical outcome
following treatment with agents targeted at the VEGF
pathway suggesting that predictive markers of these out-
comes could be clinically useful.
Sorafenib and bevacizumab have some common toxici-
ties, such as hypertension (HT), diarrhea, and gastroin-
testinal perforation [4,5]. However, sorafenib confers
frequent cutaneous side effects, including hand-foot skin
reaction (HFSR; palmar-plantar dysesthesia; acral ery-
thema) and rash in many individuals while bevacizumab
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confers HFSR in a limited number of individuals. Both in-
vitro  and  in-vivo  evidence support that HT, results
directly from the pharmacologic activity of VEGF inhibi-
tors [6]. Recently, we demonstrated that sorafenib-
induced HFSR was directly related to cumulative
sorafenib dose, that HT and HFSR development coin-
cided, and that HFSR is more prevalent in individuals
being treated with a combination of sorafenib and bevaci-
zumab targeting the VEGF receptor and the VEGF
growth factor, respectively. A pharmacokinetic interac-
tion was not observed [7]. Taken together, these results
suggest that HFSR and HT may both be related to the
activity of anti-VEGF and anti-VEGFR therapy; thus, HT
and HFSR may also be markers for a greater degree of
response in patients treated with sorafenib and bevaci-
zumab. Inter-individual genetic variation in the VEGF
pathway may also alter both the toxicity and response to
these agents.
The VEGFR2 gene contains two SNPs that are located
in exons 7 and 11 and result in nonsynonymous amino
acid changes at residues 297 Val>Ile and 472 His>Gln in
the third and fifth immunoglobulin like (Ig-like) domains
of VEGFR2 receptor, respectively. The Ig-like domain 3 is
critical for binding to the VEGF ligand [8], while domains
4-7 contain structural features that inhibit VEGFR2 sig-
naling in the absence of VEGF [9]. HEK293 s cells that
were transfected with VEGFR2 V297I SNP had signifi-
cantly low VEGF binding efficiency regardless of
VEGFR2 H472Q genotype, while variant VEGFR2
H472Q allele had minimal effect on VEGF binding effi-
ciency [10].
We hypothesize that 1) the development of HT and
HFSR following anti-VEGF therapy with bevacizumab
and sorafenib is a marker for response to these drugs; 2)
that since both toxicities are related to the activity of
these agents, the development of a single toxicity (i.e. HT)
would increase the risk of developing the other toxicity
(i.e. HFSR); and 3) that functional SNPs in VEGFR2 could
alter antiangiogenesis treatment response or outcome by
affecting the VEGF signalling pathways. To this end, we
determined if HT and HFSR were associated with pro-
gression free survival or overall survival, and if develop-
ment of HT increased the risk of developing HFSR in
patients with various solid tumors being treated with
sorafenib and/or bevacizumab. We also determined if
genetic polymorphisms in the VEGFR2  gene modified
the relationship between toxicity and survival endpoints
as well as the relationship between coincidence of HT
and HFSR.
Methods
Patients and treatment
The analyses were performed on genomic DNA from 178
patients (143 males and 35 females) with solid tumors
who received sorafenib (VEGFR2 inhibitor) and/or beva-
cizumab (anti-VEGF) with or without other agents.
These patients were enrolled in six phase I or II clinical
trials at the National Cancer Institute (Table 1). Two
phase II trials (BAY-CRPC and APC-CRPC;
NCT00093431 and NCT00091364 respectively on clini-
caltrials.gov) in patients with castrate resistant prostate
cancer (CRPC) administered sorafenib 400 mg bid and a
combination of thalidomide (200 mg qhs), bevacizumab
and docetaxel (15 mg/kg plus 75 mg/m2 day 1, q 21 days),
respectively [11,12]. Two other phase II trials (BAY-
NSCLC and BAY-CRC; NCT00100763 and
NCT00343772 respectively) treated patients with non-
small cell lung cancer (NSCLC) [13] and colorectal can-
cer (CRC), respectively with sorafenib 400 mg bid and a
combination of sorafenib (400 mg bid) and cetuximab
(400 mg/m2 loading dose in week 1 + 250 mg/m2 i.v.
week). Two phase I trials (BAY-BEV and BAY-KS;
NCT00098592 and NCT00304122 respectively) adminis-
tered sorafenib plus bevacizumab (200 mg bid + 5 mg/m2
i.v. q15 days) [14] and sorafenib with or without a pro-
tease inhibitor (starting dose of 200 mg qd/bid ± starting
dose of 200 mg qd) respectively to patients with solid
tumors and Kaposi's sarcoma.
The most severe grades of common, sorafenib treat-
ment associated toxicities, namely rash, desquamation,
diarrhea, HFSR, HT and fatigue were used for analysis.
Toxicities were graded based on the National Cancer
Institute common toxicity criteria version 3.0. This retro-
spective genotyping analysis was approved by the
National Cancer Institute Institutional Review Board.
Genotyping
DNA was extracted from plasma or whole blood using
QiaBlood extraction kit (Qiagen, Valencia, CA). Geno-
typing for two VEGFR2 loci was performed by single/
nested PCR using the following primers at an annealing
temperature of 60°C: rs1870377 (T/A) F1:5'-CAGAAT-
CACCCTACACAGATGC-3', R1: 5'-TTCCCAGAAT
AGCTGCTTCC-3', F2: 5'-TGGTACTGCTAAAAGT-
CAATGG-3', R2:5'-GGCTGCGTTGGAAGTTATTT-3';
and rs2305948 (C/T) F4: 5'-GGTTTGAACCCAAGTTC-
CTG-3', R4: 5'-CACTTTCACCACGTGAGGTTT-3', F5:
5'-TGGCCTCCCTAACAAGAAAA-3', R5: 5'-TGGT-
GTCCCTGTTTTTAGCA-3'. The details of the genotyp-
ing procedure are described elsewhere [15]. The
sequencing PCR was carried out with Big Dye (v3.1,
Applied Biosystems, Foster City, CA) using the following
PCR primers: rs1870377 (T/A) F3: 5'-CCTGGAAGTC-
CTCCACACTT-3', R3: 5'-AACCAAAGTCTGAAT
CTTTTCCTT-3'; and rs2305948 (C/T) F6: 5'-CCCT-
GACAAATGTGCTGTTC-3', R6: 5'-TGCTGTGCTTT-
GGAAGTTCA-3'. The PCR products were then
sequenced on an ABI Prism 3130xl Genetic AnalyzerJ
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Table 1: Summary of patients included in analysis
Trial Tumor type Treatment (s) n Frequency of Toxicity [n = (%)] Median PFS (months)
HT ≥ grade 2 HFSR ≥ grade 2 HT < grade 2 
vs. ≥ grade 2
Log-Rank P = HFSR < grade 
2 vs. ≥ grade 2
Log-Rank P =
APC-CRPC mCRPC Bevacizuamb + Thalidomide + Docetaxel 60 15 (25.0) 4 (6.7) 14.9 vs. 31.5 0.0009 N/A* ND*
BAY-BEV ST Sorafenib + Bevacizumab 27 15 (55.6) 13 (48.1) 3.7 vs. 11.9 0.052 3.7 vs. 12.6 0.094
BAY-CRPC† mCRPC Sorafenib 46 9 (19.6) 7 (15.2) 3.7 vs. 1.8 0.067 2.0 vs. 3.1 0.29
BAY-NSCLC NSCLC Sorafenib 22 9 (40.9) 10 (45.5) 1.9 vs. 4.6 0.19 2.9 vs. 3.7 0.38
BAY-CRC CRC Sorafenib + Cetuximab 18 1 (5.6) 2 (11.1) N/A* ND* 4.7 vs. 8.7 0.0065
BAY-KS‡ KS Sorafenib +/- Protease inhibitor 8 3 (37.5) 2 (25.0) N/A* ND* N/A* ND*
*Not done (ND). Patients were not evaluated in this analysis due to low frequency of toxicity (i.e. APC-CRPC vs. HFSR and BAY-CRC vs. HT) or due to limited PFS data (KS).
†3 Patients participating on this trial were also treated on APC-CRPC.
‡Two patients on BAY-KS trial received only sorafenib.
C: Caucasian, AA: African-American, Others: Hispanic or Asians, mCRPC: metastatic castrate resistant prostate cancer, NSCLC: non-small cell lung cancer, CRC: colorectal cancer, KS: Kaposi's 
sarcoma, ST: solid tumors, HFSR: hand-foot skin reaction syndrome, NA: not applicableJain et al. Journal of Experimental & Clinical Cancer Research 2010, 29:95
http://www.jeccr.com/content/29/1/95
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(Applied Biosystems) as per the instructions from the
manufacturer.
Statistical considerations
The progression free or overall survival based on geno-
type or toxicity groups (grade ≥ 2/grade < 2) was esti-
mated by the Kaplan-Meier method [16] and compared
by the exact log-rank test. Deviation from Hardy-Wein-
berg equilibrium was tested separately for different eth-
nic groups, using the Chi-squared test. The impact of
genotypes on treatment-associated toxicities and the
association between toxicities were assessed by Fisher's
exact test. All statistical analyses were two-tailed at a pre-
specified significance level of < 0.05. In view of the
exploratory nature of analysis, P-values were not formally
corrected for multiple testing. SAS for Windows version
9.1.3 was used for these statistical analyses.
Results
Genotyping data
The genotype and allele frequencies of studied VEGFR2
SNPs are shown in Table 2. Both VEGFR2 SNPs were in
Hardy-Weinberg equilibrium (P ≥ 0.77) when evaluated
in Caucasian patients (n = 140) and African American
patients (n = 17). Hardy-Weinberg equilibrium was not
assessed in Hispanics and Asians (n = 13). There was no
linkage between the two VEGFR2 SNPs (P > 0.05) in any
of the studied populations.
HT and HFSR as phenotypic markers for PFS and OS
Because drug-induced toxicities may be directly related
to the activity of bevacizumab and sorafenib, we hypothe-
sized that these toxicities may also predict the progres-
sion free survival (PFS) and overall survival (OS)
following anti-VEGF therapy. Patients on BAY-KS were
not included in the survival analysis since this cohort was
small with limited survival data. When the other 5 clini-
cal trials presented in Table 1 were examined individually,
we determined that HT was associated with prolonged
PFS in patients treated with bevacizumab on the APC-
CRPC and BAY-BEV trials (P = 0.0009, and P = 0.052
respectively). The median PFS difference was 14.9 (HT <
grade 2, n = 45) versus 31.5 months (HT ≥ grade 2, n = 15)
in patients participating on the APC-CRPC trial (Figure
1A), and 3.7 (HT < grade 2, n = 12) versus 11.9 months
(HT ≥ grade 2, n = 15) for those on BAY-BEV (Figure 1B).
Development of HT was not related to survival following
sorafenib without bevacizumab (BAY-NSCLC and BAY-
CRC; P > 0.19), with a single exception where patients on
BAY-CRPC with < grade 2 HT (n = 37) actually had mar-
ginally non-significantly prolonged survival when com-
pared to those individuals with HT ≥ grade 2 (n = 9; 1.8
versus 3.6 months respectively; P = 0.067).
As is indicated in Table 1, incidence of ≥ grade 2 HFSR
was also associated with PFS in patients with colon can-
cer treated with sorafenib (P = 0.0065) with those patients
having HFSR (n  = 2) having a significantly longer
response to sorafenib (8.7 months) than those without
HFSR (4.7 months, n = 16). HFSR and PFS were either
marginally not associated in patients on BAY-BEV (P =
0.094), or were not associated on BAY-NSCLC and BAY-
CRPC (P ≥ 0.29). However, since each group treated with
sorafenib had a similar trend (i.e. patients with HFSR
always had a longer median PFS) with a small number of
Table 2: Genotype and allele frequencies for SNP in VEGFR2 loci for patients treated with sorafenib and/or bevacizumab, 
with or without other agents
Allelic variant N Genotype frequencies, N (%) Allelic frequencies
Wt Het Var p q
VEGFR2 H472Q 170
C* 140 82 50 8 0.76 0.24
AA*1 7 1 2 5 0 0 . 8 5 0 . 1 5
Others 1 3 940 N / A N / A
VEGFR2 V297I 170
C* 140 114 25 1 0.9 0.1
AA* 17 9 6 2 0.71 0.29
Others 1 3 850 N / A N / A
* Genotyping information was not available for n = 7 Caucasians and n = 1 African American included in subsequent analyses.
C: Caucasians, AA: African-Americans, Others: Hispanic or Asians, Wt: wild-type genotype, Het: heterozygous genotype, Var: homozygous 
variant genotype, p and q are standard Hardy-Weinberg nomenclature for allele frequencies.Jain et al. Journal of Experimental & Clinical Cancer Research 2010, 29:95
http://www.jeccr.com/content/29/1/95
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patients in each group (n ≤ 46), we pooled survival data
obtained from the above trials to analyze the relationship
between HFSR and PFS with greater statistical power.
The pooled analysis significantly improved the relation-
ship between PFS and HFSR with patients who developed
HFSR following treatment with sorafenib, either as single
agent or in combination with bevacizumab or cetuximab
(n = 32), having a median PFS of 6.1 months compared
with 3.6 months in patients without these toxicities (n =
81; P = 0.0003, Figure 1C). However, this pooled analysis
should be interpreted with caution given that it is present
only when heterogeneous groups of data obtained from
patients are combined together. Association of these tox-
icities with OS was not significant with a single striking
exception where those patients receiving the BAY-BEV
combination had a significantly longer survival (P  =
0.0093) if they developed hypertension during therapy
(29 months, n = 14) when compared to those that did not
develop hypertension (5.7 months, n = 12; Figure 1D). No
other toxicity (i.e., rash/desquamation, diarrhea, or
fatigue) was related to PFS (P > 0.05) for either drug.
Increased risk of developing HFSR along with HT
We next hypothesized that since HT and HFSR originate
from the activity of bevacizumab and sorafenib, the
development of a single toxicity (i.e. HT) would increase
the risk of developing the other (i.e. HFSR). Analysis of
association between toxicities revealed that individuals
with HT grades < 2 had a lower risk of developing HFSR
grades ≥ 2 (19 of 126 patients, 15.1%) than those patients
with HT grades ≥ 2 (19 of 52 patients, 36.5%, OR (95%CI)
= 3.2 (1.5-6.8), P  = 0.0024). Therefore, increased HT
grade conferred a significantly increased risk of also
developing HFSR.
Figure 1 Kaplan-Meier curve of progression-free survival following treatment with bevacizumab in combination with docetaxel and thal-
idomide, n = 60 (A), or bevacizumab in combination with sorafenib, n = 27 (B), or sorafenib alone or in combination with bevacizumab, or 
cetuximab in patients with prostate cancer, various solid tumors, colon cancer, or NSCLC n = 113 (C), or overall survival following treatment 
with bevacizumab in combination with sorafenib, n = 26 (D) versus development of ≥ Grade 2 toxicity - - or < Grade 2 toxicity ------ as indi-
cated on each respective figure. Respective P = 0.0009, P = 0.052, P = 0.0003, and P = 0.0068 by a two-tailed log-rank test.Jain et al. Journal of Experimental & Clinical Cancer Research 2010, 29:95
http://www.jeccr.com/content/29/1/95
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VEGFR2 H472Q and V297I genotypes vs. treatment 
associated toxicities and survival following sorafenib and/
or bevacizumab therapy
T h e  a s s o c i a t i o n s  o f  H T  a n d  H F S R  w i t h  t h e  V E G F R 2
H472Q polymorphism were significant when all trials
were pooled (see Table 3). Frequencies of HT and HFSR
for patients carrying the variant VEGFR2 H472Q poly-
morphism was almost double the HT/HFSR frequency of
wild-type allele carriers who recieved therapies against
VEGF pathway (HT: variants, 39% vs. wild-type, 21%, OR
(95%CI) = 2.3 (1.2 - 4.6), P = 0.0154; HFSR: 33% vs. 16%,
OR (95%CI) = 2.7 (1.3 - 5.6), P = 0.0136). Similar results
were obtained for following subgroups: patients treated
with only sorafenib (HT: 32% vs. 18%, P = 0.25; HFSR:
39% vs. 16%, P  = 0.045) and patients treated with
sorafenib as at least one of the therapies (with or without
bevacizumab; HT: 42% vs. 21%, P = 0.0210; HFSR: 44% vs.
20%, P = 0.0063). These results must also be interpreted
with caution given that multiple clinical trials with differ-
ent toxicity incidence were pooled together. VEGFR2
genotype was not related to other toxicities (i.e., rash/
desquamation, diarrhea, or fatigue; P > 0.05).
To determine whether the aforementioned association
between HT and HFSR is confounded by VEGFR2
H472Q, the association between any two of the factors
(i.e., HT, HFSR and VEGFR2 H472Q) with stratification
by the remaining factor were tested. The results were
consistent with the hypothesis that the associations are
independent of each other. Genotype-toxicity relation-
ships for other toxicities and studied VEGFR2 SNPs were
not significant (Table 3). The VEGFR2 V297I SNP was
not related to toxicity, and neither VEGFR2 genotype was
related to any survival endpoint in any of the individual
clinical trials in spite of the relationship with toxicity.
Conclusions
W e hypothesized that 1) increased HT and HFSR were
markers for increased response duration in individuals
treated with bevacizumab and/or sorafenib; 2) that since
these toxicities are likely derived from the activity of bev-
acizumab and sorafenib, the development of HT would
increase the risk of also developing HFSR; and 3) that
VEGFR2 genotypic variation may be responsible for alter-
a t i o n s  i n  t h e  a c t i v i t y  o f  b ev a c i z u m a b  a n d / o r  s o r a f e n i b
therapy that would manifest in associations with toxicity
or clinical outcome following treatment with these
agents. The results of the present study confirm a previ-
ously published study where HFSR development was
noted to be related to PFS in patients with various solid
tumors receiving doses of sorafenib between 300-600 mg
bid [17], and a small study that HT is related to bevaci-
zumab response [18]. Moreover, those receiving combi-
nation therapy with bevacizumab and sorafenib that
developed hypertension enjoyed a greater than 5-fold
increase in overall survival following therapy initiation.
Consistent with our previous results [7], the development
of HT was also directly related to the incidence of HFSR,
further suggesting that these two toxicities are markers
for the activity of anti-VEGF therapy. This study is the
first to evaluate VEGFR2 H472Q status; carriers of 472Q
a l l e l e s  w e r e  m o r e  l i k e l y  t o  e x p e r i e n c e  H T  a n d  H F S R ,
although the relationship between genotype and toxicity
was independent of the relationship between the two
types of toxicity, and was not related to any of the studied
survival endpoints.
The physiological basis for bevacizumab- and
sorafenib-induced HT and HFSR is currently unknown
although they most likely originate from the activity of
these drugs altering signaling through several targets (i.e.,
VEGF, Raf-1, wild-type B-Raf, mutant b-raf V599E,
VEGFR2, VEGFR3, PDGFR-β, Flt3, c-KIT and p38)
[19,20]; recent data suggests that the VEGF pathway
directly contributes [6,7]. Once these pathways are
altered, HT may develop because of decrease in vascular
surface area [6], and HFSR may develop due to ineffi-
ciency of the repair of microtrauma originating from use
of the hands and feet [21]. In spite of the unknown origin
of these toxicities, our data are consistent with the
hypothesis that HT and HFSR are related to the activity
of these drugs. The data also suggest that these toxicities
Table 3: Comparison of toxicities between wild type and variant allele groups for VEGFR2 SNPs
Toxicity grade ≥2
N (%*)
VEGFR2 H472Q VEGFR2 V297I
wt allele var allele p-value† Wt allele var allele p-value†
HT 22 (21.4) 26 (38.8) 0.0154 38 (29.0) 12 (30.8) 0.84
HFSR 16 (15.5) 22 (32.8) 0.0136 28 (21.4) 10 (25.6) 0.66
Rash:desquamation 17 (25.0) 13 (28.9) 0.67 23 (27.7) 9 (30.0) 0.82
Diarrhea 14 (20.6) 7 (15.6) 0.62 19 (22.9) 3 (10.0) 0.18
Fatigue 12 (17.7) 6 (13.3) 0.61 14 (16.9) 4 (13.3) 0.78
*% of total patients in that group,†p-values are based on Fisher's exact test. wt: wild-type, var: variant.Jain et al. Journal of Experimental & Clinical Cancer Research 2010, 29:95
http://www.jeccr.com/content/29/1/95
Page 7 of 8
are markers for prolonged response, and in the case of
sorafenib and bevacizumab coadministration, prolonged
survival benefit from these therapies. Others have also
observed that the severity of rash in patients with NSCLC
is directly related to EGF-RTK inhibition by tyrosine
kinase inhibitors, and that this cutaneous toxicity is also a
marker for increased survival [17,22]. Moreover, it has
also been suggested that rash brought on by EGF-path-
way inhibitors could be useful for optimal dose titration
[17]. Therefore, future studies directly evaluating the
development of HT and HFSR as markers for effective
dosing of these bevacizumab and sorafenib are warranted
in order to decrease the incidence of toxicity and improve
response.
Interestingly, VEGFR2 genotype may also be related to
the incidence of both HT and HFSR independently, but
does not confound the relationship between the two tox-
icities. These data suggest that the development of these
toxicities is related to signaling through the VEGF path-
way, at least in part, although the polymorphism in
VEGFR2 is not the sole factor responsible for the rela-
tionship between HT and HFSR. Given the heterogeneity
of the clinical trials under study, the lack of a relationship
between VEGFR2 genotype and PFS may be due to low
statistical power and it is hoped that future studies in
homogeneous populations will validate the relationship
between VEGFR2 polymorphism and survival.
The present analysis is inconsistent with a previous
report where it was determined that patients with breast
cancer reported significantly longer OS for patients who
developed HT on bevacizumab and paclitaxel combina-
tion than patients without this toxicity [23]. The present
data were obtained retrospectively from clinical studies
that were not designed to retain patients on the basis that
toxicity was a marker for efficacy. Indeed, a greater pro-
portion of patients carrying the 472H/Q substitutions
were removed from the trials due to toxicity (14%) than
those carrying wild-type or variant genotypes (9%),
although this was not statistically significant (data not
shown). This is not surprising given the association of
VEGFR2 variants and toxicity. However, since those car-
rying this genotype also had a better response in general,
it is possible that the desirable long-term benefit of the
treatment may not have been enjoyed in patients being
removed from therapy prior to tumor progression due to
toxicity.
In conclusion, our data indicate that HT and HFSR are
markers for prolonged progression free survival in
patients treated with bevacizumab and/or sorafenib,
patients receiving a combination of both agents that
develop HT have a large increase in treatment-related
survival, and that the development of HT on these agents
increases the risk of also developing HFSR. The associa-
tion with toxicity was not significant with respect to over-
all survival. When VEGFR2 genotypes were considered,
the present data suggest that those carrying 472Q alleles
at H472Q are at an increased risk of developing both HT
and HFSR following bevacizumab, although the SNP is
not related to either progression free survival or overall
survival. Given the exploratory pilot nature of this study,
it is hoped that future studies will validate these results
and provide a mechanism by which toxicity is related to
PFS and VEGFR2 genotypic variation is related to toxic-
ity.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
LJ, TMS, BCE, CEB, and DKP carried out experiments; ECK, WLD, SK, RY, and GG
treated the patients and collected the data for the study; LJ, TMS, DV, and DL
conducted final statistical analysis; Study was conceived by TMS, RD, JV, and
WDF; WDF provided financial support. All authors have read and approved the
final manuscript.
Acknowledgements
This study was supported in part by the Intramural Research Program of the 
National Cancer Institute, National Institutes of Health, Bethesda, MD. We thank 
our data managers Cynthia Graves, Sonja Crandon, Qinghua Ge (Roger), Shveta 
Tiwari, and Kathleen Wyvill, and most of all, our patients who participated in 
these trials. The content of this publication does not necessarily reflect the 
views or policies of the Department of Health and Human Services, nor does 
mention of trade names, commercial products, or organization imply endorse-
ment by the U.S. Government.
Author Details
1Clinical Pharmacology Program, Center for Cancer Research, National Cancer 
Institute, (9000 Rockville Pike), Bethesda, (20892), USA, 2Department of 
Pharmaceutics, School of Pharmacy, Virginia Commonwealth University, (410 N 
12th Street, Richmond, 23298, USA, 3Medical Oncology Branch, Center for 
Cancer Research, National Cancer Institute, (9000 Rockville Pike), Bethesda, 
(20892), USA, 4Department of Internal Medicine, University of Pisa, (55 Via 
Roma), Pisa, (56126), Italy, 5Biostatistics and Data Management Section, 
National Cancer Institute, (6116 Executive Boulevard), Bethesda, (20852), USA, 
6Molecular Pharmacology Section, Center for Cancer Research, National Cancer 
Institute, (9000 Rockville Pike), Bethesda, (20892), USA and 7HIV and AIDS 
Malignancy Branch, National Cancer Institute, (9000 Rockville Pike), Bethesda, 
(20892), USA
References
1. Gomez-Raposo C, Mendiola M, Barriuso J, Casado E, Hardisson D, 
Redondo A: Angiogenesis and ovarian cancer.  Clin Transl Oncol 2009, 
11:564-571.
2. Griffioen AW, Molema G: Angiogenesis: potentials for pharmacologic 
intervention in the treatment of cancer, cardiovascular diseases, and 
chronic inflammation.  Pharmacol Rev 2000, 52:237-268.
3. Rini BI: Vascular endothelial growth factor-targeted therapy in 
metastatic renal cell carcinoma.  Cancer 2009, 115:2306-2312.
4. Gressett SM, Shah SR: Intricacies of bevacizumab-induced toxicities and 
their management.  Ann Pharmacother 2009, 43:490-501.
5. Porta C, Paglino C, Imarisio I, Bonomi L: Uncovering Pandora's vase: the 
growing problem of new toxicities from novel anticancer agents. The 
case of sorafenib and sunitinib.  Clin Exp Med 2007, 7:127-134.
6. Launay-Vacher V, Deray G: Hypertension and proteinuria: a class-effect 
of antiangiogenic therapies.  Anticancer Drugs 2009, 20:81-82.
7. Azad NS, Aragon-Ching JB, Dahut WL, Gutierrez M, Figg WD, Jain L, 
Steinberg SM, Turner ML, Kohn EC, Kong HH: Hand-foot skin reaction 
increases with cumulative sorafenib dose and with combination anti-
Received: 10 May 2010 Accepted: 14 July 2010 
Published: 14 July 2010
This article is available from: http://www.jeccr.com/content/29/1/95 © 2010 Jain et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Journal of Experimental & Clinical Cancer Research 2010, 29:95Jain et al. Journal of Experimental & Clinical Cancer Research 2010, 29:95
http://www.jeccr.com/content/29/1/95
Page 8 of 8
vascular endothelial growth factor therapy.  Clin Cancer Res 2009, 
15:1411-1416.
8. Fuh G, Li B, Crowley C, Cunningham B, Wells JA: Requirements for 
binding and signaling of the kinase domain receptor for vascular 
endothelial growth factor.  J Biol Chem 1998, 273:11197-11204.
9. Tao Q, Backer MV, Backer JM, Terman BI: Kinase insert domain receptor 
(KDR) extracellular immunoglobulin-like domains 4-7 contain 
structural features that block receptor dimerization and vascular 
endothelial growth factor-induced signaling.  J Biol Chem 2001, 
276:21916-21923.
10. Wang Y, Zheng Y, Zhang W, Yu H, Lou K, Zhang Y, Qin Q, Zhao B, Yang Y, 
Hui R: Polymorphisms of KDR gene are associated with coronary heart 
disease.  J Am Coll Cardiol 2007, 50:760-767.
11. Aragon-Ching JB, Jain L, Gulley JL, Arlen PM, Wright JJ, Steinberg SM, 
Draper D, Venitz J, Jones E, Chen CC, et al.: Final analysis of a phase II trial 
using sorafenib for metastatic castration-resistant prostate cancer.  BJU 
Int 2009, 103:1636-1640.
12. YM Ning JG, Arlen P, Latham L, Retter A, Wright J, Parnes H, Pinto P, Figg 
WD, Dahut WL: Phase II trial of thalidomide, bevacizumab, and 
docetaxel in patients (pts) with metastatic androgen-independent 
prostate cancer (AIPC).  American Society of Clinical Oncology (ASCO) 2007.
13. M Gutierrez SK, Allen D, Turkbey B, Choyke P, Wright JJ, Kurkjian C, 
Giaccone G, Doroshow JH, Murgo AJ: A phase II study of multikinase 
inhibitor sorafenib in patients with relapsed non-small cell lung cancer 
(NSCLC).  American Society of Clinical Oncology (ASCO) 2008.
14. Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, 
Minasian L, Sarosy G, Kotz HL, Premkumar A, et al.: Combination targeted 
therapy with sorafenib and bevacizumab results in enhanced toxicity 
and antitumor activity.  J Clin Oncol 2008, 26:3709-3714.
15. Sissung TM, Baum CE, Deeken J, Price DK, Aragon-Ching J, Steinberg SM, 
Dahut W, Sparreboom A, Figg WD: ABCB1 genetic variation influences 
the toxicity and clinical outcome of patients with androgen-
independent prostate cancer treated with docetaxel.  Clin Cancer Res 
2008, 14:4543-4549.
16. Kalbfleisch J D, Prentice R L: The Statistical Analysis of Failure Time Data 2nd 
edition. New York: John Wiley and Sons; 1980. 
17. Strumberg D, Awada A, Hirte H, Clark JW, Seeber S, Piccart P, Hofstra E, 
Voliotis D, Christensen O, Brueckner A, Schwartz B: Pooled safety analysis 
of BAY 43-9006 (sorafenib) monotherapy in patients with advanced 
solid tumours: Is rash associated with treatment outcome?  Eur J Cancer 
2006, 42:548-556.
18. Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C, 
Cascinu S: Arterial hypertension correlates with clinical outcome in 
colorectal cancer patients treated with first-line bevacizumab.  Ann 
Oncol 2009, 20:227-230.
19. Lyons JF, Wilhelm S, Hibner B, Bollag G: Discovery of a novel Raf kinase 
inhibitor.  Endocr Relat Cancer 2001, 8:219-225.
20. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, 
Zhang X, Vincent P, McHugh M, et al.: BAY 43-9006 exhibits broad 
spectrum oral antitumor activity and targets the RAF/MEK/ERK 
pathway and receptor tyrosine kinases involved in tumor progression 
and angiogenesis.  Cancer Res 2004, 64:7099-7109.
21. Segaert S, Chiritescu G, Lemmens L, Dumon K, Van Cutsem E, Tejpar S: 
Skin toxicities of targeted therapies.  Eur J Cancer 2009, 45(Suppl 
1):295-308.
22. Susman E: Rash correlates with tumour response after cetuximab.  
Lancet Oncol 2004, 5:647.
23. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart 
DA, Hancock B, Davidson N, Gralow J, et al.: Association of vascular 
endothelial growth factor and vascular endothelial growth factor 
receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel 
compared with paclitaxel plus bevacizumab in advanced breast 
cancer: ECOG 2100.  J Clin Oncol 2008, 26:4672-4678.
doi: 10.1186/1756-9966-29-95
Cite this article as: Jain et al., Hypertension and hand-foot skin reactions 
related to VEGFR2 genotype and improved clinical outcome following beva-
cizumab and sorafenib Journal of Experimental & Clinical Cancer Research 
2010, 29:95